- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03794635
An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer
A Communication-Based Intervention for Cancer Patient-Caregiver Dyads to Increase Engagement Treatment Planning and Reduce Caregiver Burden
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
For Patients:
- Self-identifies as Latino/a
- Diagnosis of poor prognosis advanced cancer defined as: (1) locally advanced or metastatic cancer (i.e., thoracic, gynecological, genitourinary cancer, pancreatic or lymphoma) or (2) disease progression following at least first line treatment
- Fluent in English or Spanish
- Age 18 or older
- Has a primary informal caregiver (as defined by an unpaid individual who provides the patient with emotional, physical, and/or practical support) who is willing and able to participate in the study
- Score of </= 10 on the Blessed Orientation-Memory-Concentration Test (BOMC)
- To assess whether a prognostic discussion occurred, the oncologist must answer "Yes" to the following: "Have you discussed the any of the following with Mr./Mrs./Ms. [INSERT PATIENT"S NAME]: If his/her cancer is curable, if his/her cancer is terminal, or his/her life expectancy: Yes/No Note: This question will be included in the email in which study staff request permission to contact the patient.
- As per self-report, residency in New York or ability to complete sessions in New York to ensure that provision of TAC is covered by the professional licenses of TAC interventionists (i.e., social workers licensed in New York State) - AIMS 2 and 3 ONLY
- Able to communicate over the phone for sessions
- Willingness to be audio-recorded for assessments and study sessions
For Caregivers:
- Is a primary informal caregiver (as defined by an unpaid individual who provides the patient with emotional, physical, and/or practical support) for a MSK patient
- Fluent in English or Spanish
- Age 18 or older
- Score of </= 10 on the Blessed Orientation-Memory-Concentration Test (BOMC)
- As per self-report, residency in New York or ability to complete sessions in New York to ensure that provision of TAC is covered by the professional licenses of TAC interventionists (i.e., social workers licensed in New York State) - AIMS 2 and 3 ONLY
- Able to communicate over the phone for sessions
- Willingness to be audio-recorded for assessments and study sessions
Psychosocial expert eligibility requirements:
- Current clinical practice and/or research with advanced cancer patients
- A history of 5+ years working with advanced cancer patients. Experts across disciplines (e.g., social work, psychology) may be enrolled.
- Fluent in English as self-reported by a fluency of "Very well"
Exclusion Criteria:
For Patients
- As judged by the consenting professional, treating physician or self-report, too weak or cognitively impaired to participate in the intervention and complete the assessments
- Receiving hospice at the time of enrollment
- Deemed inappropriate for the study by their treating physician
- As per medical record or self-report, currently being treated for schizophrenia, substance use or dependence, and/or bi-polar disorder
For Caregivers:
- As judged by the consenting professional, treating physician or self-report, too weak or cognitively impaired to participate in the intervention and complete the assessments
- As per self-report, currently being treated for schizophrenia, substance use or dependence, and/or bi-polar disorder
Patient-Caregiver Dyads:
- Both dyad members respond "b" or "d" on the item in Appendix K, "How would you describe your/the patient"s health status: a) Relatively healthy, b) Relatively healthy and terminally ill, c) Seriously ill but not terminally ill, or d) Seriously and terminally ill" and respond "months" on the item "When you think about your/the patient's life expectancy, do you think in terms of months or years."
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Patients
Latino/a advanced cancer patients
|
The current intervention consists of seven, weekly,45-minute sessions conducted over the telephone using the TAC manual workbook. MSK-approved platforms (such as Webex or Cisco Jabber) can be used for telephone calls in this study. There will be two versions of the intervention used for this study:
Characteristics of prognostic discussions between patients and caregivers and health providers will be assessed at baseline and post-intervention. |
|
Experimental: Caregivers
Caregivers of Latino/a advanced cancer patients
|
The current intervention consists of seven, weekly,45-minute sessions conducted over the telephone using the TAC manual workbook. MSK-approved platforms (such as Webex or Cisco Jabber) can be used for telephone calls in this study. There will be two versions of the intervention used for this study:
Characteristics of prognostic discussions between patients and caregivers and health providers will be assessed at baseline and post-intervention. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Feasibility of patient-caregiver communication-based intervention defined by participant enrollment
Time Frame: 3 months
|
3 months
|
|
Feasibility of patient-caregiver communication-based intervention defined by participant retention
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kelly Trevino, PhD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Male Urogenital Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplastic Processes
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Pathological Conditions, Signs and Symptoms
- Hemic and Lymphatic Diseases
- Lymphoma
- Neoplasm Metastasis
- Urogenital Neoplasms
Other Study ID Numbers
- 18-530
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Novartis PharmaceuticalsBristol-Myers SquibbTerminatedNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaItaly, Singapore, Australia, China, Germany, South Korea, Japan
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Epizyme, Inc.CompletedFollicular Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumors | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal LymphomaUnited Kingdom
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Lymphoplasmacytic... and other conditionsUnited States, Canada
-
IGM Biosciences, Inc.ADC Therapeutics S.A.TerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Juno Therapeutics, a Subsidiary of CelgeneCompletedFollicular Lymphoma | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma | Mantle-cell LymphomaUnited States
-
Lymphoma Study AssociationCompletedLymphoma, Large B-Cell, Diffuse | Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone LymphomaFrance
-
Emory UniversityNational Cancer Institute (NCI); AstraZenecaRecruitingMantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Lymphoproliferative Disorder | Indolent Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
Clinical Trials on Weekly 45 minute Sessions
-
University of Texas at AustinCompletedMultiple SclerosisUnited States
-
Carilion ClinicVirginia Polytechnic Institute and State UniversityCompletedQuality of Life | Self Efficacy | Behavior, Health | Cancer of EndometriumUnited States
-
University of Houston DowntownActive, not recruitingPeripheral NeuropathyUnited States
-
Medical University of GrazKristiania University CollegeRecruitingPhysical Activity | Cardiometabolic HealthAustria
-
Rigshospitalet, DenmarkActive, not recruitingCommunication | Education | Pediatrics | PlayDenmark
-
Carilion ClinicNational Institutes of Health (NIH); Virginia Polytechnic Institute and State... and other collaboratorsCompletedQuality of Life | Obesity | Endometrial Cancer | Sedentary Behavior | SurvivorshipUnited States
-
Izmir Dr Suat Seren Chest Diseases and Surgery...Not yet recruitingChronic Obstructive Pulmonary DiseaseTurkey
-
Washington State UniversityOklahoma State UniversityCompletedHypertensionUnited States
-
Memorial Sloan Kettering Cancer CenterWeill Medical College of Cornell UniversityRecruitingBreast Cancer | Colorectal Cancer | Lung Cancer | Prostate CancerUnited States
-
Centre Hospitalier Universitaire de NīmesDirex Systems GmbHWithdrawn